We are live on
!
Find out more
BJCM
Blue Jay Capital Management Portfolio holdings
AUM
$147M
1-Year Est. Return
64.18%
This Fund
S&P 500
This Quarter
Est. Return
+1.23%
1 Year Est. Return
+64.18%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$166M
AUM Growth
-$17.4M
(-9.5%)
Cap. Flow
-$23.6M
Cap. Flow
% of AUM
-14.27%
Top 10 Holdings %
Top 10 Hldgs %
69.92%
Holding
25
New
8
Increased
3
Reduced
4
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BCR
CR Bard Inc.
BCR
|
+$11.4M |
| 2 |
SHPG
Shire pic
SHPG
|
+$11.1M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$11M |
| 4 |
Labcorp
LH
|
+$11M |
| 5 |
Boston Scientific
BSX
|
+$10.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$12.8M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$12.7M |
| 3 |
WMGI
Wright Medical Group Inc
WMGI
|
+$11.9M |
| 4 |
Neurocrine Biosciences
NBIX
|
+$11.5M |
| 5 |
Illumina
ILMN
|
+$10.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.58% |
| 2 | Miscellaneous | 7.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CLVS
1
DELISTED
Clovis Oncology, Inc.
CLVS
| $13.3M | 8.01% |
298,982
-36,018
| -11% | -$1.27M |
|
|
QGENF
2
DELISTED
QIAGEN NV
QGENF
| $12.3M | 7.42% |
438,572
+138,572
| +46% | +$3.88M |
|
|
TSRO
3
DELISTED
TESARO, Inc.
TSRO
| $12.1M | 7.28% |
89,695
-30,305
| -25% | -$3.82M |
|
4
Ironwood Pharmaceuticals
IRWD
$704M
| $11.8M | 7.13% |
922,209
+56,559
| +7% | +$714K |
|
|
BCR
5
DELISTED
CR Bard Inc.
BCR
| $11.8M | 7.1% |
+52,377
| New | +$11.4M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
| $11M | 6.65% |
+90,134
| New | +$11M |
|
|
HOLX
7
DELISTED
Hologic
HOLX
| $11M | 6.62% |
273,478
-31,996
| -10% | -$1.23M |
|
8
Incyte
INCY
$25.7B
| $11M | 6.62% |
109,371
-18,798
| -15% | -$1.83M |
|
|
9
Labcorp
LH
$26.5B
| $10.9M | 6.58% |
+98,940
| New | +$11M |
|
|
10
Boston Scientific
BSX
$69.3B
| $10.8M | 6.5% |
+498,303
| New | +$10.9M |
|
|
SHPG
11
DELISTED
Shire pic
SHPG
| $10.6M | 6.43% |
+62,500
| New | +$11.1M |
|
|
DERM
12
DELISTED
Dermira, Inc.
DERM
| $10.6M | 6.41% |
350,000
+75,000
| +27% | +$2.42M |
|
13
Bristol-Myers Squibb
BMY
$136B
| $9.94M | 6% |
+170,000
| New | +$9.29M |
|
14
Edwards Lifesciences
EW
$51.8B
| $9.65M | 5.83% |
+309,087
| New | +$10M |
|
15
ResMed
RMD
$32.9B
| $9M | 5.43% |
+145,000
| New | +$8.88M |
|
|
16
Biogen
BIIB
$32.6B
| – | – |
-40,996
| Closed | -$12.8M |
|
|
17
BioMarin Pharmaceuticals
BMRN
$12.9B
| – | – |
-137,595
| Closed | -$12.7M |
|
|
18
Illumina
ILMN
$33B
| – | – |
-60,930
| Closed | -$10.8M |
|
|
MASI
19
DELISTED
Masimo
MASI
| – | – |
-166,131
| Closed | -$9.88M |
|
|
20
Neurocrine Biosciences
NBIX
$15.8B
| – | – |
-226,501
| Closed | -$11.5M |
|
21
Perrigo
PRGO
$2.07B
| – | – |
-100,000
| Closed | -$9.23M |
|
22
Smith & Nephew
SNN
$12.1B
| – | – |
-325,000
| Closed | -$10.7M |
|
|
MDRX
23
DELISTED
Veradigm Inc. Common Stock
MDRX
| – | – |
-600,000
| Closed | -$7.9M |
|
|
NUVA
24
DELISTED
NuVasive, Inc.
NUVA
| – | – |
-129,680
| Closed | -$8.64M |
|
|
WMGI
25
DELISTED
Wright Medical Group Inc
WMGI
| – | – |
-486,180
| Closed | -$11.9M |
|
Similar funds
BCM
RJA
RP
ACPVT
SFA
KL
AIM
KFS
Blue Jay Capital Management's Q4 2016 Portfolio in Review
As of Q4 2016, Blue Jay Capital Management held 25 positions worth $166M, down 9.5% from $183M the previous quarter. Its ten largest holdings account for 70% of the portfolio.
Blue Jay Capital Management withdrew a net $23.6M in Q4 2016, closing 10 positions and reducing 4 holdings. Its most notable exit was Biogen, an estimated $12.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 96% a quarter earlier, followed by Miscellaneous.
Against the trend, Blue Jay Capital Management opened a new position in CR Bard Inc. worth $11.8M.
- Blue Jay Capital Management's largest Q4 2016 buy was CR Bard Inc.: 52,377 shares worth $11.8M.
- Blue Jay Capital Management added most to QIAGEN NV in Q4 2016, an estimated $3.88M increase.
- Blue Jay Capital Management's biggest Q4 2016 reduction was TESARO, Inc., cutting an estimated $3.82M.
- Blue Jay Capital Management fully exited Biogen in Q4 2016, selling an estimated $12.8M.
- Blue Jay Capital Management's ten largest holdings make up 70% of its $166M portfolio in Q4 2016.
- Blue Jay Capital Management opened 8 new positions and closed 10 in Q4 2016.
- Blue Jay Capital Management's portfolio value fell 9.5% quarter-over-quarter to $166M.
Based on Blue Jay Capital Management's 13F filing for Q4 2016, filed 13 Feb 2017.